Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06996236
PHASE2

Brimonidine Eye Drops in the Prevention of Myopia Progression

Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

View on ClinicalTrials.gov

Summary

Study to determine the efficacy of alpha-2 adrenergic drugs (brimonidine) in the prevention of myopia progression. Given that the drugs used so far have limited efficacy and side effects (loss of near vision, photophobia), it may be an interesting contribution to such treatment at low cost, and to avoid the expense of managing the complications of myopia that develop throughout life.

Key Details

Gender

All

Age Range

6 Years - 14 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2025-07

Completion Date

2027-07

Last Updated

2025-05-30

Healthy Volunteers

No

Conditions

Interventions

DRUG

Treatment with brimonidine eye drops 0.025%

Treatment with brimonidine eye drops 0.025%, instilled once a day at night, with simultaneous occlusion of the lower lacrimal punctum to avoid its systemic absorption, for 2 years.

Locations (1)

Hospital Universitario Ramón y Cajal

Madrid, Madrid, Spain